C-YRNHomega-3 epoxyeicosanoid analogs, mitochondrial protection, anti-inflammatory small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this clinical trial is to learn about the treatment effects of the investigational new drug OMT-28 in patients with Primary Mitochondrial Disease. The main question\[s\] it aims to answer are: * Is OMT-28 safe and well tolerated in this patient population? * Does OMT-28 reduce Growth Differentiation Factor 15 (GDF-15) and other relevant blood markers of mitochondrial dysfunction and inflammation? * Does OMT-28 improve symptoms of the disease, e.g. fatigue or exercise intolerance? Participants will be asked to participate in 6 study visits at an experienced clinical center, including physical examinations and exercise tests, and take the study medication regularly once per day according to the protocol. Researchers will compare for every participant the results after 3 months and 6 months of treatment with a preceding 3 month period of standard care treatment to investigate the effects of OMT-28 on clinical parameters and a number of blood parameters.
This is a randomized, double-blind, dose-finding, placebo-controlled, parallel group, multicenter, phase II study to evaluate the efficacy, safety, and popPK of three different doses of OMT-28 given once daily versus placebo in patients with persistent AF.
The aim of this first-in-human study is to assess the safety, tolerability, PK and exploratory pharmacodynamics (PD) of single and multiple oral ascending doses of OMT-28 in healthy male subjects to support further clinical development of OMT-28 in the indication of atrial fibrillation (AF) and to obtain data on food and gender effects of OMT-28 to guide dosing for Phase II trials.
%PDF-1.5 %���� 83 0 obj > endobj 104 0 obj >/Filter/FlateDecode/ID[ ]/Index[83 55]/Info 82 0 R/Length 107/Prev 454644/Root 84 0 R/Size 138/Type/XRef/W[1 3 1]>>stream h�bbd```b``� "�@$�^�v D2n�n�2`R L��Hc0�L*��'@��;'�T��L� ��՛�� �c+������t�#�� �C����t�!@��0� endstream endobj startxref 0 %%EOF 137 0 obj >stream h�b```f``������~�A���2� , ��:� M�we'�mc`�Jp4�d�����V X �H�Q�A�A��k�c'C-�|� 7C����_ z\P���`b�T�qAc �2�9� lwt@�X4�4� ����N"�� ��� � endstream endobj 84 0 obj >/Metadata 10 0 R/Pages 81 0 R/StructTreeRoot 22 0 R/Type/Catalog>> endobj 85 0 obj >/MediaBox[0 … [Nt��O;LTY�~��R�rq8�`L��i=�3V(��8 � � endstream endobj 10 0 obj >stream application/pdf Ambrose Fullalove 2018-10-30T12:58:19Z Microsoft® Word 2013 2018-11-05T09:45:55+01:00 2018-11-05T09:45:55+01:00 Microsoft® Word 2013 uuid:8c731af7-d835-4115-a59d-01dc2cdd4cfa uuid:e3bca897-a0ee-45b2-887c-42abb93bbc99 endstream endobj 11 0 obj >stream h0T0P���w�/�+Q0���L)��0 )�I0;V?�� U? 1=��� �i� endstream endobj 12 0 obj >stream h0R0P���w,-��/�p�M*�/NUp+��I��/K��w.JM,���sI
The Product-Hatchers | Max Delbrück Center Skip to main content Max Delbrück Center Main navigation Research Menu Discovery for tomorrow's medicine Discovery for tomorrow's medicine Labs & Platforms A-Z Berlin Institute for Medical Systems Biology (MDC-BIMSB) Experimental and Clinical Research Center (ECRC) Helmholtz Institute for Translational AngioCardioScience (HI-TAC) Scientific Publications Research Highlights Systems Medicine & Cardiovascular Diseases Systems Medicine & Cardiovascular Diseases Genes, Cells & Cell-based Medicine Molecular Processes & Therapie … re mission is to transfer insights from its fundamental research into practical application. The MDC ’s department of technology transfer is responsible for the requisite processes, identifying research findings with strong commercial potential and providing comprehensive support as products make their way to the market – a long and expensive process that requires the know-how of various experts and involves cooperation with businesses and diverse public fund … cost extra for each country. MDC pays for these patents from a centralized fund in order not to strain the research groups’ budgets. Promising discoveries also need a market This is the point where Ascenion comes in. Ascenion GmbH is a technology transfer company headquartered on Campus Buch which supports MDC and numerous other institutions in the field of life sciences. The MDC is a stakeholder in Ascenion via a trust. Thurow’s team and … ched in spring 2017 . Supported by the Helmholtz Association, this platform for application-oriented research facilitates close cooperation between science and industry, developing, for example, new genetic tools on a larger scale. The MD-CEL Innovation Lab, an initiative of Wolfgang Uckert’s and Zsuzsanna Izsvak’s MDC research groups, is currently being set up. The platform will also be open to other MDC groups. There is no shortage of ideas. Currently, abou … al support. Since 2008 , PreGoBio has been facilitating in-house development of application-oriented research projects by providing 150 , 000 euros annually for equipment and personnel for a period of up to three years. PreGoBio takes on two or three new projects each year, among them Wolf-Hagen Schunck’s endeavor. Thanks to this
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
CAREERS – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Join us in Pioneering a Novel Treatment of Cardiovascular and Inflammatory Diseases Commitment in 31 million beats per year OMEICOS has assembled an exceptional team of interdisciplinary and highly motivated individuals that form the backbone of our company Our team has made unprecedented scientific advancements, thanks to its d … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics Completes PMD-OPTION Study Enrollment in Primary Mitochondrial Disease Products Data Feature Plans Request Demo Sign Up for Free OMEICOS Therapeutics Completes PMD-OPTION Study Enrollment in Primary Mitochondrial Disease 30 September 2024 OMEICOS Achieves Key Milestone in Phase 2a PMD-OPTION Study of OMT-28 Berlin, Germany, September 26, 2024 – OMEICOS, a leading biopharmaceutical firm specializing in novel small molecule therapeutics, has announced the successful completion of patient enrollment for its Phase 2a PMD-OPTION study. This multi-center, open-label clinical tri
OMEICOS Therapeutics GmbH - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 OMEICOS Therapeutics GmbH Holding Company | 2013 | Germany | 10-50 | omeicos.com Holding Company | 2013 | Germany | 10-50 | omeicos.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Cardiovascular Diseases Nervous System Diseases Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data Technolog … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
OMEICOS Therapeutics Receives 2.5 million Euros in Grant | Forbion Contact Menu About us Impacting the future History Careers Strategies Human Health Formation Ventures Growth Planetary Health BioEconomy Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Responsible investment Impact on human health SFDR Planetary Health Responsible investment Impact on planetary health SFDR News & Insights News Insights Events Media resources Contact Linkedin YouTube About us Impacting the future History Careers Strategies Human Health Planetary Health Portfolio Ventures Growth BioEcono … ces News & Insights News OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study News OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study June 21, 2023 Human Health Portfolio Back Share BERLIN, GERMANY, June 21, 2023 – OMEICOS, a biopharmaceutical company … ism and physiology, announced today that the Company has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) strongly supporting the development of OMEICOS’ lead product candidate OMT-28*. The funding provided under the “KMU-innovativ: Biomedizin” program will be used to co-finance the upcoming Phase 2a clinical study evaluating OMT-28 in Primary Mitochondrial Disease (PMD) patients. The study will be conducted in leading European cl … opy; 2026 Forbion Subscribe Yes, I give permission to store and process my data Submit
LEGAL NOTICE – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Legal Notice Responsible provider in accordance with sec. 5 of the German Telemedia Act (TMG) OMEICOS Therapeutics GmbH Robert-Rössle-Straße 10 13125 Berlin Represented by Dr. Robert Fischer Contact Tel: ++49 (0)30 9489 4810 Fax: ++49 (0)30 9489 4811 [email protected] Commercial Registry Local Court Berlin-Charlottenburg Reg … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS BMBF GRANT | Dr. Robert Fischer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie P … hondrial Disease (PMD) is approaching fast. Securing today's EUR 2.5 million in grant funding from the Federal Ministry of Education and Research, Germany to complement our own investment in the upcoming Phase 2a is a major achievement for the team and will boost our ability to demonstrate OMT-28’s potential in this indication. Beyond the strong financial support, the decision adds further validation to our approach of expanding the clinical development of OMT-28 into mitocho
Robert Fischer – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Back to NEWS Robert Fischer CEO/CSO Co-Founder Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated in many clinical … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
Team - RDiscovery Skip to content – English Japanese Menu Flyout About Us Portfolio Companies Team News Contact Us About Us Portfolio Companies Team News Contact Us – English Japanese About Us Portfolio Companies Team News Contact Us – English Japanese Team radmin 2025-11-14T13:03:55+00:00 TEAM MEET THE MINDS POWERING TOMORROW’S INNOVATIONS RDiscovery’s team includes experienced professionals with deep expertise in the life sciences, biomedical industry, business, finance, and law. Our community thrives by championing collaboration, diversity, and unity. Meet the … alifornia stem cell initiative that resulted in the $8.5 billion CIRM stem cell fund and has been a long-time advisor to several governments on biomedical policy. Walter Olesiak Operating Partner Walter has over 28 years experience in business development, healthcare consulting and venture investment. Walter spent 12 years in venture investments with Mitsui Ventures, during which time he held positions as a board member or observer in 10 portfolio companies. Prior to Mitsui W … z and a Ph.D. in Endocrinology at UC Berkeley, Cancer Research Lab under an NCI Fellowship. He completed his post-doctoral training in Cancer Genomics at UC San Francisco & LBNL as a DOE Distinguished Human Genome Postdoctoral Fellow. Kyoko Matsumoto Senior Associate Kyoko has over 18 years business experience in drug discovery in the pharmaceutical industry, patent practice at a patent firm and tech transfer at Technology Licensing Organization (TLO). Prior to joining Re … hnology licensing from universities and performed technology evaluation, patent application and prosecution, license contract negotiation mainly in the biotech area. She holds a MSc in Graduate School of Pharmaceutical Science from the Tohoku University and a M.B.A from Graduate School of Management, GLOBIS University. Atsushi Uno, PhD Senior Researcher Atsushi has been engaged in research and development of DDS technology for nucleic acid drugs for 16 years at a bio-venture
Board – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Category: Board Back to NEWS Bernhard Kirschbaum Chairman Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covere … unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS. OMEICOS Therapeutics GmbH Robert-Rössle-Strasse 10 (Building 79) 13125 Berlin, Germany t +49 (0)30 9489 4810 f +49 (0)30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US ©
Top Anti-inflammatory companies | VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of S … m/ Create a Free Account to access Downloads View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgr … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Create a Free Account to Follow Companies To continue, pleas
Bernhard Kirschbaum – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Back to NEWS Bernhard Kirschbaum Chairman Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covered … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
Wolf-Hagen Schunck – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Back to NEWS Wolf-Hagen Schunck Wolf is biochemist at the Max Delbrück Center for Molecular Medicine. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Wolf’s laboratory identified 17,18-EEQ laying the scientific basis for the foundation of OMEICOS. In … unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS. Post navigation John R. Falck Omegametrix OMEICOS Therapeutics GmbH Robert-Rössle-Strasse 10 (Building 79) 13125 Berlin, Germany t +49 (0)30 9489 4810 f +49 (0)30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE D
Management – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Category: Management Back to NEWS Robert Fischer CEO/CSO Co-Founder Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
Karen Uhlmann – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Back to NEWS Karen Uhlmann Vice President Operations & IP Co-Founder Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Univer … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
Karen Uhlmann - Vice President Operations & IP at OMEICOS Therapeutics | The Org Platform Enrich Pricing Log in Sign up OMEICOS Therapeutics Karen Uhlmann Unverified Karen Uhlmann Vice President Operations & IP Contact Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin
OMEICOS Therapeutics - Leadership Team | The Org Platform Enrich Pricing Log in Sign up OMEICOS Therapeutics Teams Leadership Team Unverified Leadership Team 3 people · 0 jobs The Leadership Team at OMEICOS Therapeutics is responsible for guiding the company's strategic direction, overseeing daily operations, and fostering innovation in the development of novel molecules for atrial fibrillation treatment. Comprising the Co-founder, CEO & CSO, CBO, and VP of Operations & IP, this team ensures alignment across departments and spearheads initiatives to achieve OMEICOS' mission
OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation Berlin, Germany, April 15, 2015 OMEICOS Therapeutics, a biopharmaceutical company developing first-i … mpany has received subsidies of EUR 550,000 via Ascenion’s Spinnovator, a grant program supported by the German Ministry of Education and Research (BMBF). “The growing population of AF patients is faced with outdated and extremely limited medical treatment options. Current treatments have insufficient efficacy, risk of severe side effects, and are unable to reduce patient mortality,” said Dr. Robert Fischer, Chief Scientific Officer of OMEICOS Therapeutics. … esellschaft are in the investment phase, the VC Fonds Technologie Berlin with a fund size of EUR 60 million and the VC Fonds Kreativwirtschaft Berlin with a fund size of EUR 40 million. Both VC funds are financed by means of the Investitionsbank Berlin (IBB) and the European Fund for Regional Development (EFRE) administered by the State Berlin. Since 1997 the IBB Beteiligungsgesellschaft Berlin, in consortia with partners, has made EUR 1.006 million available to creative and … E-Mail: [email protected] Post navigation OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation OMEICOS Therapeutics GmbH Robert-Rössle-Strasse 10 (Building 79) 13125 Berlin, Germany t +49 (0)30 9489 4810 f +49 (0)30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US ©
OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Robert Fischer Omeicos Therapeutics GmbH [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a R … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events EUROMAR 2026 Gothenburg (Göteborg) Gitex AI Europe 2026 Berlin Bay … 2027) bio:cap Investival 2027 Berlin (BioCap 2027) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease Berlin, Germany, September 26, 2024 Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics: Novel therapy for the treatment of atrial fibrillation Skip to content Portfolio Investors Team News & Events Login My pitch Deutsch English Portfolio Investors Team News & Events Metanavigation About us Career Portfolio Jobs ESG Contact Login ⟨ Back to overview Press 12 December 2013 OMEICOS Therapeutics: Novel therapy for the treatment of atrial fibrillation ⌵ Our heart beats 60 to 100 times per minute, around 42 million times per year. Disturbances of the heart’s rhythm – so called arrhythmia- occur frequently, in particular in older people. Atrial fibrillation
OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation Berlin, Germany, and Boston, MA, USA, November 2 … orbion. Existing investors Vesalius Biocapital II S.A. SICAR, Remiges BioPharma Fund, SMS Group GmbH, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG and The Falck Revocable Trust participated as well. The proceeds from this round will finance PROMISE-AF, a placebo controlled, double-blinded, randomized, dose finding Phase II study on OMT-28 in maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fib … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communications Mario Brkulj or Kara Mazey Main: +49 89 2424 3494 or +1 781-235-3060 E-Mail: [email protected] Post navigation OMEICOS … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics - Remiges Ventures Remiges Ventures Menu Home What Remiges Does Team Portfolio Companies News Contact LP Portal Japanese Skip to the content Skip to the Navigation Home What Remiges Does Team Portfolio Companies News Contact LP Portal Japanese OMEICOS Therapeutics Home Portfolio Companies OMEICOS Therapeutics Portfolio Companies Portfolio Companies > OMEICOS Therapeutics OMEICOS Therapeutics 10/04/2017 https://omeicos.com/ OMEICOS Therapeutics is a Berlin Germany based private biotech company being spin-off from the Max Delbrueck Center for Molecular Medicine (MDC). The
--> --> OMEICOS jobs, careers, overview, and news by VentureLoop --> --> --> --> MENU Toggle navigation Home Job Search internships --> blog widget --> Login --> --> OMEICOS 0 Job Address Robert-Rössle-Strasse 10 Building 79, Berlin, GE 13125 Website www.omeicos.com Est. Since 2013 Investors Forbion About --> About OMEICOS OMEICOS Therapeutics has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat mitochondrial dysfunction, inflammatory, cardiovascular and other diseases. Epoxyeicosanoids activate cel
OMEICOS Skip to content Portfolio Investors Team News & Events Login My pitch Deutsch English Portfolio Investors Team News & Events Metanavigation About us Career Portfolio Jobs ESG Contact Login 2013 Backed by HTGF since Unternehmen ansehen OMEICOS Life Sciences Pharmaceuticals Cardiology / Cardiovascular Berlin Key Facts Life Sciences Pharmaceuticals Cardiology / Cardiovascular Berlin Invested since 2013 Based in Berlin About the company OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atri … recision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs. to Scopis Unternehmen ansehen 2022 Ebenbuild Digital Health Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
Omeicos is treated to $8.7m - Global Venturing Global Venturing | Omeicos is treated to $8.7m Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company
OMEICOS Therapeutics Announces Positive Phase 2 Study --> Accessibility: Skip TopNav OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) January 29, 2026 06:00 ET | Source: OMEICOS Therapeutics GmbH OMEICOS Therapeutics GmbH Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics for mitochondrial and infl
OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease Berlin, Germany, September 18, 2023 BERLIN, GERMANY, Septe … zin” program Post navigation OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study Scientific Library 3 OMEICOS Therapeutics GmbH Robert-Rössle-Strasse 10 (Building 79) 13125 Berlin, Germany t +49 (0)30 9489 4810 f +49 (0)30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA info@omeico
Earendil Labs Secures $787M in Financing | IdeaFire™ posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s Us
Cutaneous Lupus Erythematosus Treatment Strategies and Emerging Therapies | The Journal of Clinical and Aesthetic Dermatology posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Lin
Die Gesundheitswirtschaft ist ein Wachstumsmotor Eine Marke von Funke Service Anzeigen Anzeige buchen Anzeigen-Angebote Prospekte FUNKE MediaSales Trauer Weitere Angebote Tickets Spiele Gewinnspiele Leserreisen Globista Reisen Reisekataloge Mediacampus Unternehmensangebote TV Programm Experten im Fokus VBKI Engagement Berliner Woche / Spandauer Volksblatt Berliner helfen Abo-Welt Fragen und Antworten zum Abo Lesershop Digitales Themenheft Anmelden Mein Konto Sie sind angemeldet als: [email protected] Ihre Daten und Einstellungen finden Sie in Ihrem Konto Abmelden Abo Abonnieren Mein Bezirk Bezi
OMEICOS Therapeutics (Omeicos Therapeutics GmbH) Javascript is disabled in your browser Startbase requires Javascript in order to display content. Please check your browser settings and enable Javascript-Support for this website. Your browser is outdated and Startbase will not be displayed correctly. Please use a modern web-browser like Mozilla Firefox , Google Chrome , Safari or Microsoft Edge . Startbase.com Database Startups OMEICOS Therapeutics Magazine Magazine Topic Overview News Ticker Venture Clienting Focus News Interviews Reports Portraits Knowledge Base Database Startups Investors C
DE News & Media Directions Contact us Imprint Privacy Policy berlin-buch research innovation patient care education living economic development exploring berlin-buch Made in Buch Areas Videos --1-- research basic research Clinical Research --1-- innovation BiotechPark Economic Network Facts & Figures --1-- patient care Hospitals Out-Patient Clinics --1-- education offers for 7th grade on up Berlin Bioscience Academy vocational training University studies --1-- living Day care centers Schools Apartments in listed buildings Apartments in new buildings Apartments Seniors & assisted living New … ro akquirieren. Investoren sind Forbion, Vesalius Biocapital, Remiges BioPharma Fund, die SMS Group GmbH, die KFW Group, VC Fonds Technologie Berlin (IBBbet), die High-Tech Gründerfonds II GmbH & Co. KG und der Falck Revocable Trust. Das Kapital, das nun neu zur Verfügung steht wird unter anderem für die klinische Phase II mit OMT-28 eingesetzt, bei der zum ersten Mal die Substanz Vorhofflimmerpatienten gegeben wird. Dies soll im ersten Quartal 2019 soweit sein. Run … Die bisherigen Investoren Vesalius Biocapital II S.A. SICAR, Remiges BioPharma Fund, SMS Group GmbH, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG und The Falck Revocable Trust beteiligten sich ebenfalls. Seit der Gründung 2013 aus dem Max-Delbrück-Centrum für Molekulare Medizin (MDC) hat Omeicos damit mehr als 33 Millionen Euro einwerben können. Das BMBF hat Omeicos mit mehreren Millionen Euro im Rahmen des Spinnovator-Programms unterst … üngung“ menschlicher Zellen herbeizuführen. Die Ergebnisse ihrer künstlerischen Residency sind nun Gegenstand einer Ausstellung im STATE Studio Berlin. Während ihres Aufenthalts am Max-Delbrück-Center für Molekulare Medizin (MDC) stand Emilia Tikka in intensivem Ideenaustausch mit Wissenschaftlern. Die finnische Künstlerin und Designerin hatte Gelegenheit, das Potenzial einer neuen Version der Geneditierungs-Technologie CRISPR namens dCAS9 kennenzulernen. Dieses molekulare We … g der Lebensspanne hervorgegangen ist. Das von STATE Studio und MDC angestoßene Residency-Projekt beschäftigt sich mit menschlichen Träumen, die aktuelle Entwicklungen in den Biowissenschaften vorantreiben. Tikkas künstlerisches Konzept wurzelt in einer Befragung der Vision von Transhumanismus und ewigem Leben: „Mein spekulatives Szenario entwirf
development – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Category: development Back to NEWS OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) Berlin, Germany, January 29, 2026 Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready i … edizin” program Back to NEWS OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study Berlin, Germany, June 21, 2023 BERLIN, GERMANY, June 21, 2023 – OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, announced today that the Company has received a signif … ism and physiology, announced today that the Company has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) strongly supporting the development of OMEICOS’ lead product candidate OMT-28 * . The funding provided under the “KMU-innovativ: Biomedizin” program will be used to co-finance the upcoming Phase 2a clinical study evaluating OMT-28 in Primary Mitochondrial Disease (PMD) patients. The study will be conducted in leading European … Dr. Robert Fischer. The companies’ research activities has been supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communications Mario Brkulj or Kara Mazey Phone: +49 89 2424 3494 or +1 781-235-3060 E-Mail: [email protected] Back to NEWS OMEICOS Therapeu … orbion. Existing investors Vesalius Biocapital II S.A. SICAR, Remiges BioPharma Fund, SMS Group GmbH, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG and The Falck Revocable Trust participated as well. The proceeds from this round will finance PROMISE-AF, a placebo controlled, double-blinded, randomized, dose f
OUR SCIENCE – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Nature as the Blueprint for a Family of First-in-class Therapeutics Unlocking the Full Potential of Omega 3 Biology The health benefits of omega-3 fatty acids, commonly known as fish oil, are well known. Targeting the molecular mechanism behind their protective action promises a high potential to treat diseases with high unm … Scientific Library Chemistry Scientific Evidence Therapeutic Potential Clinical Application Development of robust 17,18‑EEQ analogs as potential clinical antiarrhythmic agents Adebesin et al. J Med Chem 2019 VISIT Development of metabolically robust 17,18-EEQ analogs Falck et al. J Med Chem 2011 VISIT Cardioprotective effects of CYP-derived epoxymetabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation Darwesh et al. Can J Physiol Pahrmacol 2019 VISIT … eart diseases Monti et al. Nature Med 2008 VISIT Therapeutic Potential Clinical Application Acute Respiratory Distress Syndrome ARDS: OMT-28 protects against LPS induced lung injury in mice Tsubouchi et al. Eur J Pharmacol 2025 VISIT Cardioprotective Properties of OMT-28 Kranrod et al. JBC 2024 VISIT Pulmonary Hypertension: Omega-3 epoxyeicosanoids counteract development of PH Moriyama et al. Nature Comm 2022 VISIT Endotoxemia: OMT-28 amerliorats endotoxemia Shikuma et al. Fr … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
John R. Falck – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Back to NEWS John R. Falck John is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a numb … a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids. Post navigation Dominik N. Müller Wolf-Hagen Schunck OMEICOS Therapeutics GmbH Robert-Rössle-Strasse 10 (Building 79) 13125 Berlin, Germany t +49 (0)30 9489 4810 f +49 (0)30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL
OMEICOS Skip to content Portfolio Investors Team News & Events Login My pitch Deutsch English Portfolio Investors Team News & Events Metanavigation About us Career Portfolio Jobs ESG Contact Login 2013 Backed by HTGF since Unternehmen ansehen OMEICOS Life Sciences Pharmaceuticals Cardiology / Cardiovascular Berlin Key Facts Life Sciences Pharmaceuticals Cardiology / Cardiovascular Berlin Invested since 2013 Based in Berlin About the company OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atri … recision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs. to Scopis Unternehmen ansehen 2022 Ebenbuild Digital Health Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
OMEICOS Therapeutics streamlines Ph2 trial safety reporting | Rivia posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tennis NFL Athletics … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS
OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter February 11, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Addition of 2nd independent board member positions OMEICOS well for future value creation Feb. 11, 2019 08:00 UTC -- Addition of … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com View source version on businesswire.com: https://www.businesswire.com/news/home/20190211005270/en/ Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests: MacDougall Biomedical Communications Mario Brkulj or Amanda Whelan … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Alexander Gebauer joins OMEICOS - PharmaTimes --> Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Alexander Gebauer joins OMEICOS by PharmaTimes | 27th Apr 2018 | Appointments OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, has announced the appointment of Alexander Gebauer to the Company’s Management Board. Dr Gebauer will le … Edwards Apr 8, 2026 Dale Gordon Apr 2, 2026 News alerts This field is required. Submit Latest content Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer Lundbeck to present new Vyepti and bocunebart data at EAN 2026 Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC Contact details
OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer Berlin, Germany, April 29, 2019 OMEICOS OMEICOS strengthens management team with the appointment of biopharma business development veteran Berlin, Germany, Sep … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communications Mario Brkulj or Amanda Whelan Phone: +49 89 2424 3494 or +1 781-235-3060 E-Mail: [email protected] Post navigation OMEICOS Th … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics GmbH Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Therapeutics OMEICOS Therapeutics is developing groundbreaking small molecule therapies targeting mitochondrial dysfunction and inflammatory diseases, presenting opportunities to partner or provide complementary services in drug delivery, formulation, or biomarker detection. Funding Momentum The company has secured substantial grants and funding, demonstrating strong investor confid … b Servers Media & News OMEICOS Therapeutics receives financing of $2.72M in Grant Funding. OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study Jun 20, 2023 | www.berlinbiocube.de OMEICOS Therapeutics received financing of $18.8M on Nov 20th '18. Over the last year Forbion has led several financings including a Series B financing round of €40M in Inflazome, Series C … yees 2-10 Media & News OMEICOS Therapeutics receives financing of $2.72M in Grant Funding. Jun 20, 2023 | www.berlinbiocube.de OMEICOS Therapeutics received financing of $18.8M on Nov 20th '18. Nov 19, 2019 | www.businesswire.com OMEICOS Therapeutics hired Simon Russell as Chief Business Officer on Sep 3rd '19. Sep 03, 2019 | www.biospace.com Read more news Funding & Financials $19M OMEICOS Therapeutics GmbH has raised a total of $19M of funding over 6 rounds
OUR SCIENCE – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Nature as the Blueprint for a Family of First-in-class Therapeutics Unlocking the Full Potential of Omega 3 Biology The health benefits of omega-3 fatty acids, commonly known as fish oil, are well known. Targeting the molecular mechanism behind their protective action promises a high potential to treat diseases with high unm … Scientific Library Chemistry Scientific Evidence Therapeutic Potential Clinical Application Development of robust 17,18‑EEQ analogs as potential clinical antiarrhythmic agents Adebesin et al. J Med Chem 2019 VISIT Development of metabolically robust 17,18-EEQ analogs Falck et al. J Med Chem 2011 VISIT Cardioprotective effects of CYP-derived epoxymetabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation Darwesh et al. Can J Physiol Pahrmacol 2019 VISIT … eart diseases Monti et al. Nature Med 2008 VISIT Therapeutic Potential Clinical Application Acute Respiratory Distress Syndrome ARDS: OMT-28 protects against LPS induced lung injury in mice Tsubouchi et al. Eur J Pharmacol 2025 VISIT Cardioprotective Properties of OMT-28 Kranrod et al. JBC 2024 VISIT Pulmonary Hypertension: Omega-3 epoxyeicosanoids counteract development of PH Moriyama et al. Nature Comm 2022 VISIT Endotoxemia: OMT-28 amerliorats endotoxemia Shikuma et al. Fr … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
News-20171004 - Remiges Ventures Remiges Ventures Menu Home What Remiges Does Team Portfolio Companies News Contact LP Portal Japanese Skip to the content Skip to the Navigation Home What Remiges Does Team Portfolio Companies News Contact LP Portal Japanese News-20171004 Home News News-20171004 News News Remiges joined Extension of Series B Round of Omeicos Therapeutics to expand its technology into Ophthalmology Remiges joined Extension of Series B Round of Omeicos Therapeutics to expand its technology into Ophthalmology 10/04/2017 ----------From the Omeicos Therapeutics' Press Release------- … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contact: OMEICOS Therapeutics GmbH Dr. Robert Fischer, Chief Scientific Officer and Managing Director Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com ----------unquote---------- Omeicos Therapeutics Please visit the above site fore more detail Copyright (C) 2022-2026 REMIGES Ventures. All Rig
Edita Bade – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Back to NEWS Edita Bade Head of Finance & Controlling Edita has gained more than 20 years of experience in various Finance, Controlling & Project Leader roles across a broad range of industries. Prior to joining OMEICOS, she supported the leadership team of an international Real Estate development company with the val … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
DATA PROTECTION – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Data Protection 1. Name und Kontaktdaten des für die Verarbeitung Verantwortlichen Diese Datenschutz-Information gilt für die Datenverarbeitung durch: Verantwortlicher: OMEICOS Therapeutics GmbH, Robert-Rössle-Straße 10 D-13125 Berlin Deutschland Email: [email protected] Telefon: +49 (0)30 – 9489 4810 Fax: +49 ( … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics Berlin, Germany, and Boston, MA, USA, April 27, 2018 Appointment marks further pro … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communications Mario Brkulj or Kara Mazey Main: +49 89 2424 3494 or +1 781-235-3060 E-Mail: [email protected] Post navigation OMEICOS Announ … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
Taro Inaba – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Back to NEWS Taro Inaba Taro Inaba is Founder and Managing Partner at Remiges Ventures. He has over 29 years of business experience including 19 years in start-up financing and company creation. At Remiges, Taro is engaged in technology sourcing, company creation, leading negotiation for investments and serving as director fo … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease September 26, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – O … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) January 29, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-rea … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
OMEICOS Therapeutics Secures Extension Of Series B Financing Round To Expand Its Technology Into Ophthalmology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trend … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown OMEICOS Therapeutics Secures Extension Of Series B Financing Round To Expand Its Technology Into Ophthalmology October 4, 2017 | 3 min read Twitter LinkedIn Facebook Email Print OMEICOS adds REMIGES Ventures as new investor and announces the incorporation of U.S. subsidiary OMEICOS Ophthalmics, Inc. BERLIN & … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com . Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, +49 (0) 30 9489 4810 Chief Scientific Officer and Managing Director [email protected] www.omeicos.com or Media: MacDougall Biomedical Communications Mario Brkulj, +49 89 2424 3494 [email protected] or Dr. Jacob Verghese, +49 175 501 0575 Twitter LinkedIn … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
OMEICOS Therapeutics Announces First Closing Of €8.3 Million Series B Financing Round And The Initiation Of Phase 1 Clinical Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search OMEICOS Therapeutics Announces First Closing Of €8.3 Million Series B Financing Round And The Initiation Of Phase 1 Clinical Trial March 1, 2017 | 4 min read Twitter LinkedIn Facebook Email Print BERLIN--( BUSINESS WIRE )--OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therape … for the ongoing support of our investors and anticipate this financing to fully fund the company throughout the duration of the Phase 1 clinical study, which will set the stage for a swift transition into a subsequent Phase 2 trial.” “We believe in the potential of OMEICOS’ distinctive small molecules to treat atrial fibrillation and other inflammatory and cardiovascular diseases,” said Vesalius Biocapital’s Dr. Christian Schneider. “We look forward to seeing progress with th … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com OMEICOS Therapeutics GmbH Dr. Ulrich Dauer, +49 (0) 30 9489 4810 Chief Executive Officer and Managing Director [email protected] or Dr. Robert Fischer, +49 (0) 30 9489 4810 Chief Scientific Officer and Managing Director [email protected] www.omeicos.com or Media requests: MacDougall Biomedical Communications Gre … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
OMEICOS Therapeutics Secures Continued Bmbf Support With New €1.7 Million Research Grant To Advance Its Novel Approach To Treat Cardiovascular Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development F … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search OMEICOS Therapeutics Secures Continued Bmbf Support With New €1.7 Million Research Grant To Advance Its Novel Approach To Treat Cardiovascular Diseases June 7, 2017 | 3 min read Twitter LinkedIn Facebook Email Print Clinical Trial in Atrial Fibrillation Ongoing as OMEICOS Evaluates Therapeutic Paradigm in Additional Ind … r diseases including atrial fibrillation, today announced the approval of a new grant by the German Ministry of Education and Research (BMBF). The grant of approximately €1.7 million covers half of the investment needed to advance an OMEICOS research project with the other half coming from the funds secured in a Series B round from an investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II Gmb … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer September 3, 2019 | 3 min read Twitter LinkedIn Facebook Email Print OMEICOS strengthens management team with the appointment of biopharma business development veteran Sept. 3, 2019 08:00 UTC OMEICOS strengthens manageme … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005217/en/ Contacts OMEICOS Therapeutics GmbH: Dr. Robert Fischer, CEO/CSO +49 (0) 30 9489 4810 [email protected] www.omeicos.com Media Requests: MacDougall Mario Brkulj or Amanda Whelan +49 89 2424 3494 or +1 781-235-3060 omei … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
#pmd #mitochondrialdiseases #omt28 | OMEICOS Therapeutics GmbH LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privac
German Spin-off Scores Funding to Treat Atrial Fibrillation Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by … cological treatments such as catheter ablation are also expected to increase in application due to newer and improved techniques. The growing population of AF patients is faced with outdated and extremely limited medical treatment options. Current treatments have insufficient efficacy, risk of severe side effects, and are unable to reduce patient mortality,” said Robert Fischer, CSO of OMEICOS Therapeutics. New pharmacological interventions with different mechanisms and … rensocatib: where the field goes next ADVERTISEMENT Suggested Articles New drug application for chronic kidney disease sparks $35M milestone payment Swiss Firm Launches Cancer Test That Gives Results in Minutes Truffle Capital Raises €250M Fund to Launch Life Science Startups Sensorion gets go-ahead from France for trial of drug to prevent hearing loss French Biotech Withdraws US Application for its Living Biocide Latest Articles “It’s time to Act”: EU biotech to undergo majo
MEET OMEICOS DURING JPM HEALTHCARE WEEK | OMEICOS Therapeutics GmbH LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , P
Omeicos (Group) - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 New Nvidia AI … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events EUROMAR 2026 Gothenburg (Göteborg) Gitex AI Europe 2026 Berlin Bay … 2027) bio:cap Investival 2027 Berlin (BioCap 2027) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
PIPELINE – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Making a Real Impact on Severe Human Diseases and Patient’s Life Establishing a Pipeline of Differentiated Drug Candidates OMEICOS’ pipeline is based on our proprietary compounds, developed with our industry-leading understanding of omega-3 fatty acid metabolism and biology. We have established a broad compound library, are eva … r with pre-clinical anti-inflammatory and anti-atherosclerotic data support the application of OMT-28 in the treatment of cardiometabolic syndromes. We are actively planning a proof of concept clinical study in patients with chronic inflammation in coronary artery disease on biomarkers of inflammation. In independent outcome studies, a reduction of these biomarkers has been directly associated with positive clinical outcomes. In a previously performed Phase 1 study, OMT-28 ex … nd HRS. He is a recipient of the American Heart Association’s Paul Dudley White Award. Prof. Naccarelli has published over 600 peer reviewed papers, book chapters and reviews in addition to authoring four books related to cardiac arrhythmia. He is currently on the steering committee of multiple clinical trials and has vast experience in the development and approval of multiple anti-arrhythmic agents in the USA. Gerald Naccarelli, MD, FACC, FAHA, FHRS, Bernard Trabin Chair in … nd HRS. He is a recipient of the American Heart Association’s Paul Dudley White Award. Prof. Naccarelli has published over 600 peer reviewed papers, book chapters and reviews in addition to authoring four books related to cardiac arrhythmia. He is currently on the steering committee of multiple clinical trials and has vast experience in the development and approval of multiple anti-arrhythmic agents in the USA. --> Learn more about our SCIENCE Nature as the Blueprint for a Fa … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical St … ism and physiology, announced today that the Company has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) strongly supporting the development of OMEICOS’ lead product candidate OMT-28 * . The funding provided under the “KMU-innovativ: Biomedizin” program will be used to co-finance the upcoming Phase 2a clinical study evaluating OMT-28 in Primary Mitochondrial Disease (PMD) patients. The study will be conducted in leading European … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics | Forbion Contact Menu About us Impacting the future History Careers Strategies Human Health Formation Ventures Growth Planetary Health BioEconomy Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Responsible investment Impact on human health SFDR Planetary Health Responsible investment Impact on planetary health SFDR News & Insights News Insights Events Media resources Contact Linkedin YouTube About us Impacting the future History Careers Strategies Human Health Planetary Health Portfolio Ventures Growth BioEconomy Team Sustainability Human Health … tection. OMEICOS’ small molecules are orally available but can be used in other application routes as well. OMEICOS has the exclusive, worldwide license for IP rights from Max Delbrueck Center for Molecular Medicine in Berlin, Germany, and UT Southwestern, Texas, USA, to develop its lead compound OMT-28 and has established a comprehensive pipeline of discovery and pre-clinical stage compounds. OMEICOS is financed by a strong consortium of private and public VC investors and i … private and public VC investors and its research activities are supported by a grant from the German Ministry of Education and Research (BMBF). Human Health DE Robert-Rössle-Straße 10 D-13125 Berlin omeicos.com Industry Biotech Status Current Location Germany Forbion team Holger Reithinger PhD Senior Advisor News Human Health Portfolio OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a P … opy; 2026 Forbion Subscribe Yes, I give permission to store and process my data Submit
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) Berlin, Germany, January 29, 2026 Trial … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Targeting both Inflammation and Mitochondrial Dysfunction for the treatment of Diseases with high unmet need Unlocking the Full Therapeutic Value of Natural Cell Protection Pathways OMEICOS is focused on developing therapies that have the potential for a significant impact on cardiovascular, inflammatory and mitochondrial diseases with high unm … ts in patients with Coronary Artery Disease. OMT-28 has shown potential for the application to other disease areas such as ophthalmology. Latest Press Release January 29, 2026 OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) Read more Upcoming Events May 31 – June 4, 2026 Euromit 2026 – the largest international conference on mitochondrial pathology Read more Pipeline Learn more about … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
Founders – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Category: Founders Back to NEWS Wolf-Hagen Schunck Wolf is biochemist at the Max Delbrück Center for Molecular Medicine. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Wolf’s laboratory identified 17,18-EEQ laying the scientific basis for the foundation of OM … unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS. Back to NEWS John R. Falck John is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a number of epoxy … a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids. Back to NEWS Dominik N. Müller Dominik is pharmacist and group leader at the Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine. He has over 25 years of research experience in the field. His current work is focused on the crosstalk between immune cells, vasculature and target organs of hypertension. … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation Berl … Dr. Robert Fischer. The companies’ research activities has been supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communications Mario Brkulj or Kara Mazey Phone: +49 89 2424 3494 or +1 781-235-3060 E-Mail: [email protected] Post navigation Leonardo Caló … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
financing – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Category: financing Back to NEWS OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology Berlin, Germany, and Boston, MA, USA, October 04, 2017 OMEICOS adds REMIGES Ventures as new investor and announces the incorporation of U.S. subsidiary OMEICOS Ophthalmics, Inc. OMEI … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contact OMEICOS Therapeutics GmbH Dr. Robert Fischer, Chief Scientific Officer and Managing Director Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communications Mario Brkulj or Dr. Jacob Verghese Main: +49 89 2424 3494 or +49 175 501 0575 E-Mail: … com Back to NEWS OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases Berlin, Germany, June 07, 2017 Clinical Trial in Atrial Fibrillation Ongoing as OMEICOS Evaluates Therapeutic Paradigm in Additional Indication Areas OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial … r diseases including atrial fibrillation, today announced the approval of a new grant by the German Ministry of Education and Research (BMBF). The grant of approximately €1.7 million covers half of the investment needed to advance an OMEICOS research project with the other half coming from the funds secured in a Series B round from an investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II Gmb … for the ongoing support of our investors and anticipate this financing to fully fund the company throughout the duration of the Phase 1 clinical study, which will set the stage for a swift transition into a subsequent Phase 2 trial.” “We believe in the potential of OMEICOS’ distinctive small molecules to treat atrial fibrillation and other inflam
OUR NETWORK – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION An Excellent Network Supporting the Development of a Novel Drug Class Deeply Rooted in the Biology and Chemistry of Epoxyeicosanoids OMEICOS was founded based on ground-breaking scientific discoveries in the field of omega-3 fatty acid metabolism and physiology. This research performed by the companies’ scientific founders l … unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS. Wolf-Hagen Schunck Wolf is biochemist at the Max Delbrück Center for Molecular Medicine. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Wolf’s laboratory identified 17,18-EEQ laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co … unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS. John R. Falck John is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a number of epoxyeicosatrienoi … a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids. John R. Falck John is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a number of epoxyeicosatrienoic a … a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids. Dominik N. Müller Dominik is pharmacist and group leader at the Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine. He has over 25 years of research experience in the f
NEWS & EVENTS – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Staying Up-to-date on OMEICOS Upcoming Events May 31 – June 4, 2026 Euromit 2026 – the largest international conference on mitochondrial pathology Read more close Euromit 2026 – the largest international conference on mitochondrial pathology Meet us in Anger, France, May 31– June 4 2026 https://www.euromit … ease Read more June 21, 2023 OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study Read more December 8, 2022 OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases Read more September 3, 2019 OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer Read more April 29, 2019 OMEICOS Therapeutics Anno … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.
NEWS – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Category: NEWS Back to NEWS OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) Berlin, Germany, January 29, 2026 Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERL … edizin” program Back to NEWS OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study Berlin, Germany, June 21, 2023 BERLIN, GERMANY, June 21, 2023 – OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, announced today that the Company has received a signif … ism and physiology, announced today that the Company has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) strongly supporting the development of OMEICOS’ lead product candidate OMT-28 * . The funding provided under the “KMU-innovativ: Biomedizin” program will be used to co-finance the upcoming Phase 2a clinical study evaluating OMT-28 in Primary Mitochondrial Disease (PMD) patients. The study will be conducted in leading European … r and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communications Mario Brkulj or Amanda Whelan Phone: +49 89 2424 3494 or +1 781-235-3060 E-Mail: [email protected] Back to NEWS OMEICOS Thera … Dr. Robert Fischer. The companies’ research activities has been supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com Contacts OMEICOS Therapeutics GmbH Dr. Robert Fischer, CEO, CSO Phone: +49 (0) 30 9489 4810 E-Mail: [email protected] www.omeicos.com Media requests MacDougall Biomedical Communicatio
OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Press Releases Back to NEWS OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases Berlin, Germany, December 08, 2022 OMT-28’s established safety profile, biomar … ll as Chief Business Officer OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study OMEICOS Therapeutics GmbH Robert-Rössle-Strasse 10 (Building 79) 13125 Berlin, Germany t +49 (0)30 9489 4810 f +49 (0)30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DI
COMPANY – OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION Developing Groundbreaking Therapies in Cardiovascular and Inflammatory Diseases Founded on a Fundamentally New Therapeutic Modality OMEICOS Therapeutics as a clinical stage company develops first-in-class small molecules targeting one of nature’s most important cell-protective pathways with treatment options in several indicatio … unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS. Wolf-Hagen Schunck Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientif … unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS. Backed by a Committed Investor Consortium OMEICOS has been successful in attracting a consortium of renowned healthcare investors. The company has raised a total of EUR 40 million in private equity and EUR 6.5 million in non-dilutive funding from Federal Ministry of Education and Research and from Investitionsbank Berlin. Rapid Progr … )30 9489 4811 [email protected] OMEICOS Therapeutics, Inc. c/o Remiges Biopharma Fund GP, Inc. One Broadway, 14th Floor, Cambridge, MA 02142, USA [email protected] LEGAL NOTICE DISCLAIMER DATA PROTECTION FOLLOW US © 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.